Women’s health across the reproductive lifespan in women with germline TP53 pathogenic variants: a clinical perspective
The Oncologist · 06.06.2026 · 31 (7)
DOI: 10.1093/oncolo/oyag212 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Oncologist, online erschienen am 11.06.2026. Verfasst von Naama Halpern und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Jusidman Cancer Center, Sheba Medical Center, Ramat Gan 5265601, Israel. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Germ-Line Mutation, Li-Fraumeni Syndrome, Women's Health. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Li-Fraumeni syndrome, caused by germline TP53 pathogenic sequence variants (PSVs), is among the most penetrant hereditary cancer syndromes. With broader genetic testing and improved survivorship, more women with TP53 PSVs now seek reproductive and hormonal guidance throughout their lifespan. Yet, no evidence-based framework currently exists to support women’s health care in this population. In this review, we searched the available literature and found an absence of data regarding contraception, fertility preservation, pregnancy, and menopause, resulting in inconsistent counseling and both under- and overtreatment. Drawing on analogies from other high-risk cancer syndromes and our multidisciplinary clinical experience, we present interim suggestions centered on shared decision-making, individualized hormonal management, and avoiding unnecessary interventions. These findings underscore the need for prospective studies and international registries to establish evidence-based and equitable women’s health care for women with TP53 PSVs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Jusidman Cancer Center, Sheba Medical Center, Ramat Gan 5265601, Israel.
- Gray Faculty of Medical and Health Sciences, School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, 6997801, Israel.
- The Suzanne Levy-Gertner Oncogenetics Unit, Danek Gertner Institute of Human Genetics, Sheba Medical Center, Ramat Gan 5265601, Israel.
- Department of Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan 5265601, Israel.
- Fertility Unit, Edith Wolfson Medical Centre, and Gray Faculty of Medical Sciences, Tel-Aviv University, Tel Aviv-Yafo 5822012, Israel.
- Preimplantation Genetic Diagnosis Center, Danek Gertner Institute of Human Genetics, Sheba Medical Center, Ramat Gan 6997801, Israel.
ORCID-Profile: Yossi Mizrachi, Myriam Safrai
Zitieren
APA
Halpern, N., Bernstein-Molho, R., Peerless, Y., Kventsel, I., Frenkel, Z., Mizrachi, Y., Shani, H., & Safrai, M. (2026). Women’s health across the reproductive lifespan in women with germline TP53 pathogenic variants: a clinical perspective. The Oncologist, 31(7). https://doi.org/10.1093/oncolo/oyag212
Vancouver
Halpern N, Bernstein-Molho R, Peerless Y, Kventsel I, Frenkel Z, Mizrachi Y, et al. Women’s health across the reproductive lifespan in women with germline TP53 pathogenic variants: a clinical perspective. The Oncologist. 2026;31(7). doi:10.1093/oncolo/oyag212
BibTeX
@article{Halpern2026,
author = {Halpern, Naama and Bernstein-Molho, Rinat and Peerless, Yehudit and Kventsel, Iris and Frenkel, Zehavit and Mizrachi, Yossi and Shani, Hagit and Safrai, Myriam},
title = {Women’s health across the reproductive lifespan in women with germline TP53 pathogenic variants: a clinical perspective},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {7},
doi = {10.1093/oncolo/oyag212}
}
EUVIMED